771 related articles for article (PubMed ID: 25401491)
1. Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus.
Cieślik P; Hrycek A
Autoimmunity; 2015 Jun; 48(4):242-50. PubMed ID: 25401491
[TBL] [Abstract][Full Text] [Related]
2. Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis.
Kluz J; Kopeć W; Jakobsche-Policht U; Adamiec R
Int Angiol; 2009 Jun; 28(3):192-201. PubMed ID: 19506538
[TBL] [Abstract][Full Text] [Related]
3. Pentraxin-3 levels are associated with vasculitis and disease activity in childhood-onset systemic lupus erythematosus.
Sahin S; Adrovic A; Barut K; Durmus S; Gelisgen R; Uzun H; Kasapcopur O
Lupus; 2017 Sep; 26(10):1089-1094. PubMed ID: 28420068
[TBL] [Abstract][Full Text] [Related]
4. The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary study.
Cieślik P; Semik-Grabarczyk E; Hrycek A; Holecki M
Rheumatol Int; 2022 May; 42(5):791-801. PubMed ID: 35284968
[TBL] [Abstract][Full Text] [Related]
5. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers.
Frijns R; Fijnheer R; Schiel A; Donders R; Sixma J; Derksen R
J Rheumatol; 2001 Mar; 28(3):514-9. PubMed ID: 11296951
[TBL] [Abstract][Full Text] [Related]
6. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis.
Kaplanski G; Cacoub P; Farnarier C; Marin V; Grégoire R; Gatel A; Durand JM; Harlé JR; Bongrand P; Piette JC
Arthritis Rheum; 2000 Jan; 43(1):55-64. PubMed ID: 10643700
[TBL] [Abstract][Full Text] [Related]
7. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study.
Spronk PE; Bootsma H; Huitema MG; Limburg PC; Kallenberg CG
Clin Exp Immunol; 1994 Sep; 97(3):439-44. PubMed ID: 7521807
[TBL] [Abstract][Full Text] [Related]
8. Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus.
Shimada Y; Asanuma YF; Yokota K; Yoshida Y; Kajiyama H; Sato K; Akiyama Y; Mimura T
Mod Rheumatol; 2014 Jan; 24(1):78-85. PubMed ID: 24261762
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
[TBL] [Abstract][Full Text] [Related]
10. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation.
Fazzini F; Peri G; Doni A; Dell'Antonio G; Dal Cin E; Bozzolo E; D'Auria F; Praderio L; Ciboddo G; Sabbadini MG; Manfredi AA; Mantovani A; Querini PR
Arthritis Rheum; 2001 Dec; 44(12):2841-50. PubMed ID: 11762945
[TBL] [Abstract][Full Text] [Related]
11. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1.
Ikeda Y; Fujimoto T; Ameno M; Shiiki H; Dohi K
Lupus; 1998; 7(5):347-54. PubMed ID: 9696139
[TBL] [Abstract][Full Text] [Related]
12. Vasculitis in systemic lupus erythematosus (SLE)--assessment of peripheral blood mononuclear cell activation and the degree of endothelial dysfunction: initial report.
Kluz J; Kopeć W; Jakobsche U; Prajs I; Adamiec R
Postepy Hig Med Dosw (Online); 2007 Dec; 61():725-35. PubMed ID: 18063917
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of endothelial dysfunction in patients with primary focal segmental glomerulosclerosis.
Zhang Q; Zeng C; Fu Y; Cheng Z; Zhang J; Liu Z
Nephrology (Carlton); 2012 May; 17(4):338-45. PubMed ID: 22295953
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of serum levels of adhesion molecules (sICAM-1, sVCAM-1, sE-selectin) in stable and unstable angina and acute myocardial infarction].
Bossowska A; Kiersnowska-Rogowska B; Bossowski A; Galar B; Sowiński P
Przegl Lek; 2003; 60(7):445-50. PubMed ID: 14750416
[TBL] [Abstract][Full Text] [Related]
16. Elevated soluble E-selectin in cutaneous lupus erythematosus.
Nyberg F; Stephansson E
Adv Exp Med Biol; 1999; 455():153-9. PubMed ID: 10599337
[TBL] [Abstract][Full Text] [Related]
17. Soluble adhesion molecules in pediatric rheumatic diseases.
Bloom BJ; Miller LC; Blier PR
J Rheumatol; 2002 Apr; 29(4):832-6. PubMed ID: 11950029
[TBL] [Abstract][Full Text] [Related]
18. Circulating soluble adhesion molecules in ANCA-associated vasculitis.
Ara J; Mirapeix E; Arrizabalaga P; Rodriguez R; Ascaso C; Abellana R; Font J; Darnell A
Nephrol Dial Transplant; 2001 Feb; 16(2):276-85. PubMed ID: 11158400
[TBL] [Abstract][Full Text] [Related]
19. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus.
Svenungsson E; Cederholm A; Jensen-Urstad K; Fei GZ; de Faire U; Frostegård J
Scand J Rheumatol; 2008; 37(5):352-9. PubMed ID: 18666029
[TBL] [Abstract][Full Text] [Related]
20. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes.
Glowinska B; Urban M; Peczynska J; Florys B
Metabolism; 2005 Aug; 54(8):1020-6. PubMed ID: 16092051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
